Is Now A Good Time To Invest In Candel Therapeutics Inc (NASDAQ: CADL)?

Candel Therapeutics Inc (NASDAQ:CADL) shares, rose in value on Thursday, April 04, with the stock price up by 48.10% to the previous day’s close as strong demand from buyers drove the stock to $2.49.

Actively observing the price movement in the recent trading, the stock is buoying the session at $1.68. The value of beta (5-year monthly) is 0.92. Referring to stock’s 52-week performance, its high was $1.95, and the low was $0.66. On the whole, CADL has fluctuated by 52.64% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $0, which is expected to increase to $0 for fiscal year -$0.91 and then to about $0 by fiscal year 2025.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that CADL’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CADL currently trading nearly 59.49% and 62.25% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 79.69, while the 7-day volatility ratio is showing 7.14% which for the 30-day chart, stands at 7.84%. Furthermore, Candel Therapeutics Inc (CADL)’s beta value is 0.90, and its average true range (ATR) is 0.18.

A comparison of Candel Therapeutics Inc (CADL) with its peers suggests the former has fared considerably weaker in the market. CADL showed an intraday change of 48.10% in today’s session so far, and over the past year, it grew by 76.46%%.

Data on historical trading for Candel Therapeutics Inc (NASDAQ:CADL) indicates that the trading volumes over the past 10 days have averaged 52240.0 and over the past 3 months, they’ve averaged 83.88K. According to company’s latest data on outstanding shares, there are 29.21 million shares outstanding.

Nearly 46.65% of Candel Therapeutics Inc’s shares belong to company insiders and institutional investors own 5.76% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.15 million shares as on Mar 15, 2024, resulting in a short ratio of 1.83. According to the data, the short interest in Candel Therapeutics Inc (CADL) stood at 0.51% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 0.28 million. The stock has risen by 69.26% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CADL stock heading into the next quarter.